tiprankstipranks
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market
PRLD
Prelude Therapeutics
RESEARCH TOOLSreports
Want to see PRLD full AI Analyst Report?

Prelude Therapeutics (PRLD) Income Statement

187 Followers

Prelude Therapeutics Income Statement

Last quarter (Q4 2025), Prelude Therapeutics's total revenue was $5.64M, an increase of 41.00% from the same quarter last year. In Q4, Prelude Therapeutics's net income was $-16.46M. See Prelude Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 12.14M$ 7.00M$ 0.00$ 0.00$ 0.00
Gross Profit
$ 10.43M$ 7.00M$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 115.00M$ 146.71M$ 132.28M$ 123.54M$ 113.73M
Depreciation and Amortization
$ 1.71M$ 1.77M$ 1.17M$ 1.32M$ 915.00K
EBITDA
$ -102.86M$ -137.94M$ -131.11M$ -122.22M$ -112.82M
Operating Income
$ -104.57M$ -139.71M$ -132.28M$ -123.54M$ -113.73M
Other Income/Expenses
$ 5.07M$ 12.54M$ 10.44M$ 8.10M$ 2.04M
Pretax Income
$ -99.50M$ -127.17M$ -121.83M$ -115.44M$ -111.69M
Net Income
$ -99.50M$ -127.17M$ -121.83M$ -115.44M$ -111.69M
Per Share Metrics
Basic EPS
$ -1.29$ -1.68$ -2.02$ -2.27$ -2.33
Diluted EPS
$ -1.29$ -1.68$ -2.02$ -2.27$ -2.33
Weighted Average Shares Outstanding
 76.96M 75.81M 60.36M 47.37M 47.60M
Weighted Average Shares Outstanding (Diluted)
 76.96M 75.81M 60.36M 47.37M 47.60M
Currency in USD

Prelude Therapeutics Earnings and Revenue History